Every 10-Q that AngioDynamics, Inc. (ANGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANGO filings page.
AngioDynamics (ANGO) reported net sales of $80.9 million for the three months ended August 31, 2026, up 6.9% from $75.7 million a year earlier. Gross margin rose to 59.4% from 55.3%, an increase of 410 basis points. Med Tech sales increased 13.2%, while Med Device sales increased 1.4%.
Net loss narrowed to $7.1 million ($0.17 per diluted share) from $10.9 million ($0.26) a year earlier. Operating cash use was $15.3 million, compared with $15.9 million, and cash was $34.0 million as of August 31, 2026, down from $53.9 million at May 31, 2026. Management said current cash on hand provides sufficient liquidity for anticipated capital needs for at least the next 12 months. No amounts were outstanding under its $25.0 million secured revolving credit facility as of August 31, 2026.
The modified manufacturing restructuring plan has estimated costs of $33.4 million to $38.4 million, and activities are expected to be completed in the second quarter of fiscal 2027. AngioDynamics announced Eric Honroth’s appointment as President and Chief Executive Officer and a Board member, effective November 2, 2026; Jim Clemmer will depart the Board that day.
AngioDynamics reported higher sales but remained unprofitable for the quarter ended February 28, 2026. Revenue rose 8.9% to $78.4 million, driven by 19.0% growth in Med Tech and 1.2% growth in Med Device.
Quarterly gross margin slipped to 52.9% as tariffs, inflation and Med Device mix offset volume and outsourcing benefits. Net loss widened to $8.1 million (loss per share $0.19) from $4.4 million, largely reflecting higher restructuring and CEO transition costs.
For the nine months, revenue increased to $233.6 million (up 10.0%) and net loss improved to $25.3 million (loss per share $0.61) from $27.9 million. The company ended the period with $37.8 million in cash, no debt and access to a $25.0 million revolving credit facility while continuing a multi‑year manufacturing footprint restructuring and ongoing payments under a patent settlement with BD.
AngioDynamics Inc. reported first-quarter fiscal 2026 net sales of $75.7 million, up 12.2% from the prior-year quarter, driven by Med Tech growth of 26.1% (Auryon, NanoKnife, thrombus management) and modest Med Device growth of 2.3%. Gross margin rose 90 basis points to 55.3%. The company recorded a net loss of $10.9 million (loss per share $0.26), an improvement from a $12.8 million loss a year earlier.
The company continues restructuring actions with $2.3 million in charges this quarter and $25.6 million total recorded to date. A settlement with BD (Becton, Dickinson) includes a one-time lump-sum structure and ongoing minimum annual payments; $2.5 million was paid this quarter and a contingent $3.0 million may be due depending on the Federal Circuit appeal (oral argument set for October 8, 2025). Management maintains a valuation allowance on deferred tax assets and noted continued macroeconomic and supply-chain risks. The company has a $25.0 million revolving credit facility with $0 drawn as of August 31, 2025.